07/17/2025 3:30 PM | Adaptimmune Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
05/13/2025 6:35 AM | Adaptimmune Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
05/01/2025 3:15 PM | Adaptimmune Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
04/25/2025 7:02 AM | Adaptimmune Therapeutics (Filer)
| Form DEF 14A | |
04/15/2025 7:00 AM | Adaptimmune Therapeutics (Filer)
| Form PRE 14A | |
04/14/2025 3:10 PM | Adaptimmune Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
03/24/2025 3:40 PM | Adaptimmune Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
03/24/2025 3:44 PM | Adaptimmune Therapeutics (Filer)
| Form 10-K Annual report pursuant to Section 13 or 15(d) | |
03/20/2025 6:09 AM | Adaptimmune Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
02/20/2025 4:34 PM | Adaptimmune Therapeutics (Issuer) Brewer Joanna Elizabeth (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
02/20/2025 4:35 PM | Adaptimmune Therapeutics (Issuer) Bertrand William C JR (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
Get the Latest News and Ratings for ADAP and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Adaptimmune Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
|
02/20/2025 4:30 PM | Adaptimmune Therapeutics (Issuer) Rawcliffe Adrian (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
02/20/2025 4:31 PM | Adaptimmune Therapeutics (Issuer) Norry Elliot (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
02/20/2025 4:32 PM | Adaptimmune Therapeutics (Issuer) Piccina Cintia (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
02/20/2025 4:33 PM | Adaptimmune Therapeutics (Issuer) Lunger John (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
02/14/2025 8:31 AM | Adaptimmune Therapeutics (Subject) Two Seas Capital LP (Filed by)
| Form SCHEDULE 13G | |
02/12/2025 9:25 AM | Adaptimmune Therapeutics (Subject) BAILLIE GIFFORD & CO (Filed by)
| Form SCHEDULE 13G/A | |
01/17/2025 8:15 PM | Adaptimmune Therapeutics (Issuer) Rawcliffe Adrian (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/17/2025 8:16 PM | Adaptimmune Therapeutics (Issuer) Bertrand William C JR (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/17/2025 8:17 PM | Adaptimmune Therapeutics (Issuer) Lunger John (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/17/2025 8:17 PM | Adaptimmune Therapeutics (Issuer) Norry Elliot (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/17/2025 2:07 PM | Adaptimmune Therapeutics (Subject) Norry Elliot (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
01/17/2025 1:42 PM | Adaptimmune Therapeutics (Subject) Rawcliffe Adrian (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
01/17/2025 1:50 PM | Adaptimmune Therapeutics (Subject) Bertrand William C JR (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
01/17/2025 1:59 PM | Adaptimmune Therapeutics (Subject) Lunger John (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
01/15/2025 3:15 PM | Adaptimmune Therapeutics (Issuer) Bertrand William C JR (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/15/2025 3:16 PM | Adaptimmune Therapeutics (Issuer) Lunger John (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/15/2025 3:17 PM | Adaptimmune Therapeutics (Issuer) Norry Elliot (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/15/2025 3:18 PM | Adaptimmune Therapeutics (Issuer) Piccina Cintia (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/15/2025 3:19 PM | Adaptimmune Therapeutics (Issuer) Rawcliffe Adrian (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/15/2025 2:43 PM | Adaptimmune Therapeutics (Subject) Lunger John (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
01/15/2025 2:50 PM | Adaptimmune Therapeutics (Subject) Norry Elliot (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
01/15/2025 2:34 PM | Adaptimmune Therapeutics (Subject) Rawcliffe Adrian (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
01/08/2025 9:30 AM | Adaptimmune Therapeutics (Subject) Matrix Capital Management Company, LP (Filed by)
| Form SCHEDULE 13G/A | |
12/19/2024 6:40 AM | Adaptimmune Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
12/05/2024 4:17 PM | Adaptimmune Therapeutics (Subject) Matrix Capital Management Company, LP (Filed by)
| Form SCHEDULE 13G/A | |
11/13/2024 8:04 AM | Adaptimmune Therapeutics (Subject) Matrix Capital Management Company, LP (Filed by)
| Form SC 13G/A | |
11/13/2024 8:10 AM | Adaptimmune Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
11/01/2024 4:00 PM | Adaptimmune Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
09/23/2024 3:15 PM | Adaptimmune Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
08/12/2024 6:23 AM | Adaptimmune Therapeutics (Filer)
| Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
Critical AI announcement set to ignite AI 2.0 (Ad) I just put together an urgent new presentation that you need to see right away.
In short: I believe we are mere days away from a critical announcement from a key tech leader…
One that will officially ignite “AI 2.0” – and potentially send a whole new class of stocks soaring.  Click to find out what Nvidia’s CEO might reveal… and how Sykes is preparing to ride the wave. |
08/12/2024 6:05 AM | Adaptimmune Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
08/02/2024 6:00 AM | Adaptimmune Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |